GUD

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Tuesday, April 9, 2024
Metro Toronto Convention Centre, GUD, TSX, Conference

MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m.

Key Points: 
  • MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m.
  • ET at the Metro Toronto Convention Centre in Toronto.
  • A copy of the presentation will be available at www.knighttx.com .

Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity

Retrieved on: 
Thursday, March 28, 2024
Business, Therapy, GUD, TSX, Parity, Woman

This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity.

Key Points: 
  • This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity.
  • The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to provide an overview of the largest Canadian corporations with the highest degree of gender diversity among executive ranks.
  • “We are honoured to see once again Knight Therapeutics Inc. included on the Globe and Mail’s Report on Canada’s Women Lead Here as one of the leading companies in executive gender diversity in corporate Canada and specialty pharmaceutical sector,” said Samira Sakhia, President and Chief Executive Officer of Knight.
  • In total, 97 companies earned the 2024 Women Lead Here seal, with a combined average of 45% of executive roles held by female-identifying individuals.

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Retrieved on: 
Thursday, March 14, 2024
Knight, GUD, TSX

MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening.

Key Points: 
  • MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening.
  • Following the release, Knight will hold a conference call and audio webcast.
  • Knight cordially invites all interested parties to participate in this call.

American National Bank of Texas and Good Urban Development Work to Support Homebuyer Education and Affordable Housing in Southeast Dallas’ Mill City

Retrieved on: 
Tuesday, March 26, 2024
Residential Building & Real Estate, Banking, Construction & Property, Professional Services, Philanthropy, Other Philanthropy, Other Professional Services, Fund Raising, Foundation, Other Construction & Property, Finance, Community development, AMI, Partnership, Education, Housing, RSVP, National bank, GUD, Real estate

American National Bank of Texas (ANBTX) will join with Good Urban Development (GUD), to host two free seminars as part of ANBTX’s ongoing homebuyer education series.

Key Points: 
  • American National Bank of Texas (ANBTX) will join with Good Urban Development (GUD), to host two free seminars as part of ANBTX’s ongoing homebuyer education series.
  • GUD is a joint venture between Dallas nonprofit Urban Specialists Incorporated and Lewisville-based Matthews Southwest, a full-service private real-estate development company that has spearheaded many community-oriented projects, including the recent Mill City 50, a transformative housing development in the Mill City neighborhood in Southeast Dallas.
  • The instructor-led seminars will guide participants through the process of buying — and owning — a home.
  • Topics include reviewing potential loan options and common mortgage terms as well as understanding all the steps, from applying to underwriting to closing.

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

Retrieved on: 
Thursday, February 29, 2024
ANVISA, DCR, Knight Therapeutics, TSX, DLBCL, GUD, Therapy, Health, Non-Hodgkin lymphoma, Patient, ASCT, Lenalidomide, Knight, Resolution

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.

Key Points: 
  • MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.
  • Additionally, in October 2023, Knight received pricing approval for Minjuvi® from the Drugs Market Regulation Chamber (“CMED”).
  • “In line with Knight’s commitment to advancing healthcare in Latin America, we are excited to launch Minjuvi in Brazil, an innovative treatment option for addressing a current unmet medical need,” said Samira Sakhia, Knight Therapeutics President and CEO.
  • “Knight’s team in Brazil is thrilled to make Minjuvi® available to health care professionals and centers, improving DLBCL patient care in the country,” said Cristiane Coelho, Knight Therapeutics Brazil General Manager.

Knight Therapeutics Inc. Celebrates its First Decade of Success

Retrieved on: 
Wednesday, February 28, 2024
Latin Americans, Acquisition, Knight, Marketing, TSX, Growth, GUD, Pharmacovigilance, Patient, Pharmaceutical industry

MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth.

Key Points: 
  • MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth.
  • Knight has invested over $925 million to build its unique pan-American (ex US) platform of innovative and branded generic pharmaceuticals.
  • Today, Knight has over 700 talented employees operating in Canada and 10 Latin American markets.
  • Since the completion of the acquisition of Biotoscana, Knight has entered into 11 new partnerships for 13 innovative and branded generic products.

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Retrieved on: 
Wednesday, February 21, 2024
ANVISA, Fostamatinib, TSX, ITP, GUD, SYK, Therapy, Thrombocytopenia, Patient, Knight, Pharmaceutical industry

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Key Points: 
  • MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
  • Knight has previously submitted marketing authorization applications for fostamatinib in Colombia and Mexico.
  • “This submission of fostamatinib demonstrates Knight’s continued execution of our strategy of leveraging our solid platform and expertise to bring innovative therapies for important unmet healthcare needs in Latin America,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.
    On May 24, 2022, Knight announced that it entered into an agreement with Rigel Pharmaceuticals, Inc. for the exclusive rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
  • Fostamatinib is commercially available in the United States under the brand name TAVALISSE® and in Europe under the brand name TAVLESSE® for the treatment of adult chronic ITP.

Knight Therapeutics Announces Launch of Bijuva® in Canada

Retrieved on: 
Tuesday, February 6, 2024
VMS, GUD, Uterus, Estradiol, Pan-American, Progesterone, Patient, Hot, TSX, Therapy, Capsule, Menopause, Hormone, Woman

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada.

Key Points: 
  • MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada.
  • VMS affects 60% to 80% of women entering menopause1 and are commonly known as hot flashes or flushes and night sweats.
  • Knight and TherapeuticsMD signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to BIJUVA®.
  • Under the terms of the license agreement related BIJUVA® in Canada, Knight will pay TherapeuticsMD sales milestone fees and royalties based upon certain aggregate annual sales of BIJUVA® in Canada.

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

Retrieved on: 
Thursday, January 25, 2024
Patient, GUD, Standard of care, TSX, Stomach, Absorption, Trial of the century, CNS, Pharmaceutical industry

MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America.

Key Points: 
  • MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America.
  • IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules designed for the treatment of Parkinson’s disease.
  • “This transaction builds on our strategy of expanding our CNS portfolio,” said Samira Sakhia, President and CEO of Knight.
  • “We see IPX203 as a critical innovation that can meaningfully advance the standard of care for Parkinson’s patients.”

Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

Retrieved on: 
Friday, January 19, 2024
Patient, TSX, GUD

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the sales of the antifungal Cresemba® (isavuconazole) in 2023 by its partner Knight Therapeutics Inc. (“Knight”, TSX: GUD) in Latin America exceeded the threshold triggering the first sales milestone payment for this region.

Key Points: 
  • Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the sales of the antifungal Cresemba® (isavuconazole) in 2023 by its partner Knight Therapeutics Inc. (“Knight”, TSX: GUD) in Latin America exceeded the threshold triggering the first sales milestone payment for this region.
  • David Veitch, Chief Executive Officer, said: “We are very pleased with the commercial progress that Knight has made with Cresemba, which has now triggered the first sales milestone payment from Knight for Latin America.
  • The continued growth confirms that Cresemba is serving a high medical need around the world.”
    By year-end 2023, Cresemba was marketed in more than 70 countries, including the United States, most EU member states, China, Japan and countries in Latin America.
  • According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2022 and September 2023 amounted to USD 445 million, a 22 percent growth year-on-year.1